Type 2 Diabetes Treatment: What Is MondoA?

Type 2 diabetes affects about 8% of Americans and another 25% of the population is at risk because of obesity. The condition accounts for as much as 20% of all healthcare costs in the U.S.

Photo Credit: Drug Watch

A protein called MondoA has been identified by researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) as a new potential target for drugs to prevent Type 2 Diabetes. The chronic condition accounts for between 85 and 95% of all people with diabetes.

Insulin resistance, in which insulin no longer causes the body's cells to take up the glucose from a meal and use it for energy, leads to Type 2 Diabetes. Following this, glucose continues to circulate in the blood, stimulating the pancreas to make more and more insulin, which eventually becomes so stressful that the insulin-producing cells die. This results in diabetes as the pancreas can no longer produce enough insulin to control blood glucose.

Read full article at Medical Daily and view video